Abstract Human macrophage inflammatory protein-1 beta (MIP-1β) is an M r 8,000 acidic protein that is upregulated upon stimulation in monocytes, T cells, and other lymphocytes. This protein belongs to the CC chemokine subfamily and directs the migration of specific subsets of leukocytes. The first molecular clone was isolated in 1988, and ever since there has been confusion regarding the exact number of genes encoding this and closely related proteins. PCR primers were designed from two genomic GenBank entries to conduct single-strand conformational polymorphism analysis, sequence analysis, and PCR-RFLP, and we conclude that previously isolated clones referred to as MIP-1β are derived from two genes, originally called ACT-2 and LAG-1. The two proteins share a common length and are identical at 89 of 92 amino acids. The first two amino acid differences, V12M and L20P, occur in the signal peptide, while the third, G70S, is in the mature protein. Within the transcribed region, the genes differ at 25 of 662 nucleotides. A survey of the NCBI expressed sequence tag database reveals that both genes are expressed in a variety of tissues, and five clones representing LAG-1 transcripts are alternatively spliced, with the 115-bp exon 2 omitted. Database searches for putative orthologues in other species revealed that the rabbit protein is about 80% similar to the two human proteins, while those of rat and mouse are 70-75% similar. Comparative sequence analysis of the human and animal proteins indicates substantially higher rates of protein evolution in the two rodents compared to human and rabbit.
Introduction
Macrophage inflammatory protein-1 alpha (MIP-1α) and macrophage inflammatory protein-1 beta (MIP-1β) were originally co-purified from endotoxin-stimulated mouse macrophages and defined as a single protein . Subsequent biochemical analyses revealed the distinctiveness of each protein and molecular cloning confirmed that they are encoded by different genetic loci in the mouse Sherry et al. 1988) .
The first human clones identified as the apparent orthologue to mouse MIP-1b were cDNAs from a gene called ACT-2, which represented a novel immune activation gene (Lipes et al. 1988 ) ACT-2 was isolated by differential hybridization screening of an activated T-cell library and the protein was shown to be 76% identical at the amino acid level to murine MIP-1β (Napolitano et al. 1991) . Shortly thereafter, additional human cDNA, including pAT 744 (Zipfel et al. 1989) , hH400 (Brown et al. 1989) , G-26 (Miller et al. 1989) , HC21 (Chang and Reinherz 1989) , and genomic LAG-1 (Baixeras et al. 1990 ) clones corresponding to MIP-1β were isolated by other laboratories. As the sequences from these clones were aligned, numerous differences were discovered and the presence of different alleles or even distinct, closely related genes was postulated (Baixeras et al. 1990 ). The existence of more than one gene was also supported by Southern blot analysis of genomic DNAs (Chang and Reinherz 1989; Napolitano et al. 1991) . The exact number of genes was uncertain, but Schall (1991) reported that many of the seven independently isolated MIP-1b cDNA clones differed slightly in the predicted proteins they encoded.
We are isolating and characterizing novel single nucleotide polymorphisms (SNPs) from various human chemokine genes. The goal is to use the SNPs as genetic markers in association analyses with various disease phenotypes including AIDS, asthma, and kidney disorders. One approach commonly used to identify SNPs is the polymerase chain reaction (PCR)-based single-strand conformation polymorphism technique (SSCP) (Orita et al. 1989) followed by direct sequence analysis. One outcome of our search for SNPs in the human MIP-1b gene was the discovery that certain primer pairs were amplifying more than one gene. This prompted further investigation into the genomic structure of the MIP-1b gene. Results suggest that the human MIP-1β protein is encoded by two closely related paralogous genes derived from a recent duplication event.
Materials and methods
Two genomic sequences from GenBank were used for PCR primer design. X53682 contains a 2488-bp sequence originally referred to as the lymphocyte activation gene (LAG-1) (Baixeras et al. 1990 ). AC003976 is an anonymous 123,925-kb BAC clone hCIT.91_J_4 submitted by the Whitehead Institute for Biomedical Research/MIT Center for Genome Research (WICGR) (http:// www.genome.wi.mit.edu/), and contains the ACT-2 gene in addition to other genomic elements. X53682 and AC003976 were aligned using the GAP procedure in the Wisconsin Package (1997) .
PCR was performed as follows: 30 ng of genomic DNA was amplified in a 20-µl volume in 10 mM Tris-HCl, pH 8.3, 50 mM KCl, 1.5 mM MgCl2, 200 µM of each dNTP, 6 pmol of each primer, and 0.001 units of Taq Gold DNA polymerase (PerkinElmer). PCR cycling conditions consisted of an initial 94°C denaturation step for 10 min, followed by 35 cycles of 94°C, denaturation for 30 s, 57-62°C annealing for 1 min, and 72°C extension step for 1 min, ending with a 72°C step for 5 min.
PCR for SSCP was conducted as described above with the addition of 0.04 µl of a 32 P-dCTP (3000 Ci/mmol; New England Nuclear) to each reaction. After PCR, products were digested with a restriction enzyme in the appropriate buffer (products from primers 12/13 with BsaJI and products from 3F/3R with AciI; Table 1 ). Ten microliters of stop solution (0.05% each of bromphenol blue and xylene cyanol in 100% foramide) was then added to each reaction. The products were heated at 95°C for 5 min, then quick chilled on ice. Products were separated in vertical slab gels using at least two of the following four electrophoretic conditions: (1) 6% acrylamide (37.5:1 acrylamide:bisacrylamide), 4°C at 50 W for 3.5 h, (2) 6% acrylamide (37.5:1 acrylamide:bisacrylamide) with10% glycerol, 4°C at 10 W for 8-12 h, (3) 5% acrylamide (19:1 acrylamide:bisacrylamide), room temperature at 40 W for 4-6 h; the first three conditions used 1×TBE buffer (0.09 M Tris base, 0.09 M boric acid, 1 mM Na 2 EDTA, pH 7.8), or (4) 6% acrylamide (37.5:1 acrylamide:bisacrylamide), 4°C at 50 W for 3.5 h in 1×TME buffer, pH 6.8 (0.03 M Tris base, 0.035 M 2(N-morpholino)-ethanesulfonic acid, 1 mM Na 2 EDTA pH 7.8.
PCR products were sequenced directly using Big Dye chemistry (Applied Biosystems). Products were first purified using Qiagen quick-spin columns. Electrophoresis was carried out on an ABI 377 automated fluorescent DNA sequencing machine. Nucleotide sequence alignment, consensus sequence construction, and restriction mapping were done using Sequencher software (Gene Codes).
PCR-RFLP experiments were carried out for two restriction sites distinguishing LAG-1 from ACT-2 within the sequenced regions. These were conducted on genomic DNA from 40-48 unrelated Caucasians. DNA was amplified using the appropriate primers, and PCR products were digested for 4 h in 40-µl volumes using the proper restriction enzyme and buffer (New England Biolabs). Products were separated in 3% agarose slab gels, stained with ethidium bromide, and photographed. Restriction fragments were compared in size to a molecular-weight ladder.
Results
Initially, two pairs of PCR primers (LAG-1 12/13 and 3F/3R) were designed from GenBank X53682 for SSCP (Table 1) . When they were used on genomic DNAs from 36 European Americans and 36 African Americans, the SSCP patterns revealed unusually high levels of individual variation. Subsequent sequence analyses of products from pair 3F/3R from several individuals identified numerous sites of apparent heterozygosity. These results suggested that more than one gene was being amplified. BLAST searches of the NCBI database with X53682 revealed similarity to AC003976. Alignment showed the two sequences to be 95.6% identical over the entire 2488 bp of X53682. The X53682 sequence aligned with the region of AC003976 between bp 46388 to bp 48875. To validate the sequence differences between the two clones in the protein-coding regions, primers were designed from each sequence with terminal mismatches between the two GenBank sequences. PCR amplification of genomic DNA and direct sequencing of products from six to ten individuals were carried out using the following primers: LAG-1 27/1R, LAG-1 14/15, LAG-1 18/19, ACT-2 11/12, ACT-2 1B/2B, and ACT-2 3B/14 (Table 1) . These primers are located in noncoding regions and amplify each of the three coding regions and some flanking material. Results indicated that the sequences derived from clone X53682 (LAG-1) differed from the sequences obtained from clone AC003976 (ACT-2).
The sequences of the coding and associated 5′ and 3′ flanking regions of the two genes are shown in Fig. 1 .
The transcribed regions were identical in length (662 bp), with all differences being attributable to base substitutions as opposed to insertion-deletions. A total of 155 bp, 115 bp, and 392 bp were sequenced for the putative transcribed regions of each exon, respectively. Translated amino acid sequences are included in Fig. 1 ; both full-length proteins contain 92 amino acids. The signal peptides are 23 amino acids in length. The number of nucleotide (nt) and amino acid (aa) differences between X53682 and AC003976 in each exon are -exon 1: 5 nt, 2 aa; exon 2: 0 nt, 0 aa; exon 3: 20 nt, 1 aa. Two of the three amino acid differences occur in the signal peptide, V12M and L20P. The third, G70S, is found in the mature protein.
Two restriction site differences in exon 3 (HhaI and MspI) distinguishing the genes are shown in Fig. 1 . These sites were used in PCR-RFLP assays of genomic DNA from 40-48 Caucasians to demonstrate that the variation found between the two genes identified by sequencing may be extended to a larger number of individuals. Analyses revealed that HhaI should cut LAG-1 at position 301, and MspI should cut ACT-2 at position 402.
Both of these sites were tested using primers LAG-1 18/19 and ACT-2 3B/14 and the expected results were found (RFLP results not shown).
Discussion
The LAG-1 and ACT-2 proteins differ by three amino acids, two in the signal peptide and one in the mature protein. Among the differences in the signal peptide, the valine to methonine substitution is a conservative one. The leucine to proline change involves two nonpolar residues, with proline containing a large aromatic ring. The glycine to serine change at position 70 in the mature peptide involves two polar, uncharged residues with glycine containing -H and the larger serine, -CH 2 OH as side groups.
A nuclear magnetic resonance structure is available for the ACT-2 protein (Lodi et al. 1994) . Evaluation of the three-dimensional structure seen in the protein database (http://www.rcsb.org/pdb/cgi/explore.cgi?pid= 4377977407482&pdbId=1HUM) shows that S70 is positioned in a β-pleated sheet following a tight β turn. The oxygen atom of the hydroxyl side chain is hydrogen bonded with the hydrogen atom of T67. Furthermore, the oxygen atom of S70 is hydrogen bonded with the amino group of K71. Thus, this network of hydrogen bonds stabilizes the turn and β sheet. If S70 is mutated to glycine, the network of hydrogen bonds is broken, and due to the increased flexibility of glycine, the β turn may also be destabilized. Since MIP-1β (ACT-2) is known to bind the seven-transmembrane G protein-coupled receptor CCR5 (Laurence et al. 2000) , we might assume that LAG-1 binds this receptor also. The effect of G70S on receptor binding is unknown; however, mutations at a single amino acid (F13) have been shown to affect ACT-2 binding (Laurence et al. 2000) .
Among human chemokine genes there are several additional examples of very similar paralogous gene/protein pairs or triplets. These include MIP-1α and LD78β (Irving et al. 1990 ), lymphotactin-1α and 1β (Yoshida et al. 1996) , platelet factor 4 (PF4) and platelet factor 4 variant 1 (PF4V1), and GROα, GROβ, and GROγ (Haskill et al. 1990 ). In all of these examples, the mature proteins in each group are at least 95% identical. At first glance this would suggest some redundancy in function; however, the variant amino acids may be adequate for functional distinctiveness or there may be substantial differences in transcriptional regulatory regions of the genes (Hogan et al. 1994) . Pairs of closely related chemokine genes have also been reported in other species and this reflects the fact that this multigene family has undergone a series of tandem duplications events, some very recent, throughout the evolutionary history of mammals (Modi and Yoshimura 1999; Tasaki et al. 1999) .
One important question involves the tissue location and timing of expression, and patterns of inducibility of each of these two genes. Earlier studies showed that ACT-2 (and/or LAG-1) is not strongly expressed in resting lymphocytes but is rapidly induced in stimulated T cells, B cells, and monocytes (Napolitano et al. 1991; Ziegler et al. 1991) , and in CD3 -natural killer cells (Baixeras et al. 1990 ). These studies used full-length cDNA clones as hybridization probes in Northern blots, which would hybridize to mRNA from both genes, and would not pick up low-level transcripts.
Another approach for evaluating expression is to examine the NCBI human expressed sequence tagged (EST) database. Using the LAG-1 sequence of Fig. 1 as a query sequence, the 28 best matches were tabulated ( Table 2) . Inspection of these revealed three important observations.
All EST clones could be classified as either LAG-1 or
ACT-2 based upon the intergenic differences outlined in Fig. 1 . Furthermore, there is no evidence that more than two expressed sequences exist in the database. 2. Both LAG-1 and ACT-2 are expressed in a greater variety of tissues (e.g., parathyroid tumor, prostate, kidney, pineal gland, spleen, germ cell tumors) than was previously expected (this could be due to lymphocyte contamination). 3. Five of the LAG-1 clones derived from four different libraries are alternatively spliced transcripts. Each of these clones is missing exon 2 that contains 115 nucleotides (Table 2 ). Not only is the predicted protein shorter due to the loss of exon 2, but since the exon 1/2 and 2/3 junctions split codons, there is a frameshift beginning with exon 3. This results in a different amino acid sequence encoded by exon 3, the utilization of an upstream termination codon, and the deletion of two terminal amino acids (Fig. 2) . From Fig. 2 it is important to also note that the alternatively spliced protein is missing three of the four cysteine residues critical for intrastrand disulfide bonding. If proper folding is prevented, this shorter protein may not bind CCR5.
Both LAG-1 (Baixeras et al. 1990 ) and ACT-2 (Napolitano et al. 1991) have been assigned to the long arm of Chromosome (Chr) 17 using in situ chromosome hybridization. The ACT-2 gene is located in the region 46,388-48,875 bp on the 123,925-bp AC003976 clone; however, LAG-1 is not found on this clone. A search of the NCGBI website for Chr 17 (http://www.ncbi.nlm.nih. gov/genome/seq/chr.cgi?CHR=17&SRT=ppos&MIN=100 &ORG=Hs) reveals that neither AC003976 nor X53682 is found on any larger genomic contig. This means that the closest these two genes could be to one another is about 46 kb. This is consistent with the results of Tasaki and co-workers (1999) who presented a physical map of the beta chemokine cluster based upon BAC and YAC clones. They showed that AT744.2 (LAG-1) and MIP-1b/AT744.1 (ACT-2) are separated by the LD78b and LD7g5′F genes and are about 80 kb apart. One important issue concerns the gene duplication event creating LAG-1 and ACT-2. Aligning X53682 and AC003976 reveals an overall similarity of about 95.6%. This means 2.2% divergence along each branch of an evolutionary tree since the two genes last shared a common ancestor. If one assumes a neutral substitution rate of 0.2-0.4% per site per million years (Wu and Li 1985) , then the duplication event creating LAG-1 and ACT-2 occurred 6-12 million years ago (MYA). Old World monkeys are thought to have last shared a common ancestor with anthropoid apes about 30 MYA, and humans with gorilla and chimpanzee, 5-12 MYA (Sibley and Alquist 1987) . This predicts that the duplication event coincided with the radiation of the anthropoids. To more accurately date the duplication event and determine which gene is ancestral, requires comparing LAG-1 and ACT-2 sequences from other species.
Unfortunately, inspection of GenBank indicates that these genes are unavailable for any other primate species. However, there are five mouse (M23503, M35590, X62502, AF128218, AF128219), one rat (U06434), and one rabbit (D17402) MIP-1β sequence available. Aligning these amino acid sequences reveals no variation among the five mouse entries, but a number of differences between mouse MIP-1β, rat MIP-1β, rabbit MIP-1β, human ACT-2, and human LAG-1 (Fig. 3) . Examination of the amino acid composition of the three positions distinguishing the two human genes in the three animal species shows that residue 12 is uninformative while positions 20 and 70 provide conflicting interpretations regarding ancestry. Thus, due to the limited amount of comparative sequence data for these genes, we are unable to determine whether LAG-1 or ACT-2 is the ancestral human gene.Possibly, both of these, or other closely Table 2 Expressed sequence tagged (EST) sequences for the LAG-1 and ACT-2 genes. Asterisked entries are alternatively spliced clones lacking exon 2 (see Fig. 2 To extend the analysis of the animal sequences, evolutionary distances were computed for all pairwise comparisons (Table 3 ). This table indicates that the human proteins are more similar to that of the rabbit than to those of rat or mouse. Furthermore, the rabbit and human proteins are about 20% diverged while those of rat and mouse show about 18.5% divergence. Primates (human) and lagomorphs (rabbit) are thought to have last shared a common ancestor about 75 MYA, while rat and mouse diverged about 15 MYA. If these dates are accurate, then the rate of protein evolution in the two rodents is about five times greater (18.5/15 vs 20/75) than that seen in human and rabbit. Accelerated rates of molecular evolution have been reported for many rodent genes (Wu and Li 1985) , and this may reflect the extraordinary ability of rodents to diversify rapidly and expand into novel ecological niches. However, the genes being compared between species may not be orthologous (resulting from speciation), but are, rather, paralogous (resulting from duplication).
Gene nomenclature
The formal gene symbols SCYA4 and SCY4L are cur--rently used to reference the following clones or genes: CCL4, CCL4L, AT744.1, AT744.2, HC21, H400, SISg, (see http://cytokine.medic.kumamotou.ac.jp/CFC/CK/CCG/ CCG.html). One option for future naming is that MIP-1β be synonymous with SCYA4 and ACT-2, and LAG-1 with SCYA4L. It would probably be least confusing if the names MIP-1β and LAG-1 were used in the future. It may be noted that commercially available MIP-1β protein from R&D Systems (Minneapolis, Minn; catalogue No. 271-BME), or PeproTech (Rocky Hill, N.J.; catalog No. 300-09) is ACT-2. Fig. 3 Amino acid sequence alignment of the human LAG-1 (X53682), human ACT-2 (AC009736), rat (D17402), mouse (M23503), and rabbit (U06434) MIP-1β proteins carried out using the Wisconsin Package (1997) PILEUP program 
